Review Article
Discovery of Biomarkers for Osteosarcoma by Proteomics Approaches
Table 4
Clinicopathological features of osetosarcoma tissue samples for chemosensitivity study.
| | Sample name | Age | Gender | Histological subtype | Site | Huvos grading | Preoperation chemotherapy agents | Mstastasis
(months) | Followup
(months) | Status |
| | Huvos I |
| | OS03 | 9 | Female | Telangiectatic | Proximal femur | 1 | MTX, ADR/CDDP | 46 | 54 | DOD | | OS17 | 13 | Female | Osteoblastic | Proximal tibia | 1 | HD-MTX | 15 | 51 | DOD | | OS18 | 14 | Male | Osteoblastic | Proximal tibia | 1 | HD-MTX, ADR/CDDP | — | 73 | NED | | OS32 | 19 | Male | Osteoblastic | Distal femur | 1 | HD-MTX, CDDP/ADR, | — | 47 | NED | | OS36 | 63 | Female | Osteoblastic | Metatarsus | 1 | IFO, CDDP/ADR | — | 18 | NED | | OS41 | 18 | Male | Osteoblastic | Pelvis | 1 | IFO, CDDP/ADR | At diagnosis | 18 | DOD | | OS47 | 14 | Male | Chondroblastic | Proximal femur | 1 | IFO, CDDP/ADR | At diagnosis | 15 | AWD |
| | Huvos III and IV |
| | OS11 | 19 | Male | Osteoblastic | Distal tibia | 3 | HD-MTX, ADR/CDDP | 18 | 88 | NED | | OS25 | 13 | Male | Li-Fraumeni | Distal femur | 3 | HD-MTX, ADR/CDDP | 47 | 48 | DOD | | OS27 | 15 | Female | Osteoblastic | Distal femur | 3 | HD-MTX, IFO, ADR/CDDP | At diagnosis | 26 | DOD | | OS35 | 19 | Female | Fibroblastic | Distal tibia | 3 | HD-MTX, CDDP/ADR | — | 40 | NED | | OS38 | 18 | Male | Osteoblastic | Distal tibia | 3 | IFO, CDDP/ADR | — | 26 | NED | | OS48 | 8 | Male | Osteoblastic | Proximal humerus | 3 | IFO, CDDP/ADR | — | 14 | NED | | OS24 | 14 | Female | Osteoblastic | Distal femur | 4 | HD-MTX, CDDP/ADR, | — | 60 | NED | | OS28 | 9 | Female | Osteoblastic | Proximal tibia | 4 | HD-MTX, CDDP/ADR, | 6 | 51 | NED | | OS39 | 16 | Male | Chondroblastic | Proximal tibia | 4 | IFO, CDDP/ADR | — | 26 | NED |
|
|
